Myeloma

The latest news, research, and perspectives in multiple myeloma. Myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells that produce monoclonal immunoglobulin. These neoplastic cells result in characteristic clinical features that include bone lytic lesions, hypercalcemia, renal insufficiency, and anemia.

Overview
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The phase III study included patients who received at least one prior line of therapy.
Read More
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Blood Cancers Today Staff WritersMyeloma | September 21, 2023
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Leah LawrenceLatest Issue | September 20, 2023
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Thomas Martin, MDVideo Insights | September 19, 2023
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
Sagar Lonial, MD, FACPVideo Insights | September 19, 2023
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Cecilia BrownMyeloma | September 4, 2023
Researchers examined tumor-intrinsic factors that promote multiple myeloma antigen escape.
Ajay Nooka, MD, FACPMyeloma | August 28, 2023
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Cecilia BrownMyeloma | August 21, 2023
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
Cecilia BrownMyeloma | August 21, 2023
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | August 16, 2023
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
Cecilia BrownMyeloma | August 14, 2023
The bispecific antibody received Breakthrough Therapy Designation from the FDA in November 2022.
Cecilia BrownMyeloma | August 14, 2023
There was no significant difference in the number of mutations present at diagnosis between the two groups of patients.
Cecilia BrownMyeloma | August 14, 2023
The researchers used a cumulative deficit approach to calculate a frailty index score at diagnosis and at landmark intervals.
Cecilia BrownMyeloma | August 10, 2023
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
Cecilia BrownMyeloma | August 9, 2023
More than one-quarter of the patients required a dose reduction due to adverse events.
Leah SherwoodMyeloma | August 2, 2023
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Shambavi Richard, MDMyeloma | July 17, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Claudio Cerchione, MD, PhDMyeloma | July 5, 2023
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Cecilia BrownMyeloma | July 4, 2023
Patients with clonal plasma cells in the autograft had a significantly lower MRD-negative CR rate after transplant.
Cecilia BrownMyeloma | July 3, 2023
The trial compared ciltacabtagene autoleucel with standard of care in patients with MM who were refractory to lenalidomide.
Cecilia BrownMyeloma | June 30, 2023
The supplemental BLA submission is supported by data from the CARTITUDE-4 study.
Cecilia BrownMyeloma | June 29, 2023
Researchers used a simulated partitioned survival model to compare overall survival among three treatment strategies.
Cecilia BrownMyeloma | June 27, 2023
A recent study showed significant differences in OS based on the t(4;14) translocation breakpoint area in MM.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panelists highlight key data presented at ASCO 2023.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 26, 2023
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
Blood Cancer TalksBlood Cancer Talks | June 24, 2023
The hosts discuss the latest data on CAR-T from the summer conference season.
Leah SherwoodMyeloma | June 23, 2023
In this video interview from EHA, Dr, Munshi shares the close-out efficacy and safety results from CARTITUDE-1.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 23, 2023
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 23, 2023
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 22, 2023
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Leah SherwoodMyeloma | June 20, 2023
The FDA has put a clinical hold on the investigational new drug CART-ddBCMA.
Blood Cancer TalksBlood Cancer Talks | June 13, 2023
Dr. Chari and the hosts also discuss a phase I trial of fixed-duration cevostamab, as well as a phase I trial of ABBV-383.
Thomas Martin, MDMeeting News | June 12, 2023
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | June 9, 2023
The panel considers triplet versus quadruplet therapy for myeloma induction.
Cecilia BrownMyeloma | June 8, 2023
The response rates seen with talquetamab in the trial were "very impressive," Dr. Schinke said.
Blood Cancers Today Staff WritersMyeloma | June 8, 2023
Researchers are evaluating the combination to establish a recommended phase III dose for the first-line setting.
Cecilia BrownMyeloma | June 7, 2023
The study evaluated teclistamab in patients with relapsed or refractory multiple myeloma.
Blood Cancers Today Staff WritersMyeloma | June 7, 2023
In the trial, patients received talquetamab at 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
Cecilia BrownMyeloma | June 7, 2023
The phase II study evaluated linvoseltamab, a bispecific antibody targeting BCMA and CD3, in relapsed or refractory MM.
Chadi Nabhan, MD, MBA, FACPMyeloma | June 6, 2023
Dr. Mohan discusses her 2023 ASCO Annual Meeting presentation with Chadi Nabhan, MD, MBA, FACP.
Blood Cancers Today Staff WritersMyeloma | June 5, 2023
Patients treated with the higher dose had higher overall response rates.
Leah SherwoodMyeloma | June 5, 2023
Dr. Bansal and colleagues presented the results of the study at the 2023 ASCO Annual Meeting.
Blood Cancers Today Staff WritersMyeloma | June 5, 2023
Approximately one-third of the heavily pretreated patients in the small study responded to therapy.
Blood Cancers Today Staff WritersMyeloma | June 4, 2023
The overall response rate was 87.8% with 73% of patients achieving complete response.
Blood Cancers Today Staff WritersMyeloma | June 4, 2023
The median time from last dose of selinexor to anti-BCMA therapy was eight weeks.
Blood Cancers Today Staff WritersMyeloma | June 4, 2023
Improvement of nontarget lesions was noted in five of 25 patients (20%).
Leah SherwoodMyeloma | June 2, 2023
Health care disparities have been an "ongoing issue" for patients with cancer, especially in multiple myeloma.
Blood Cancers Today Staff WritersMyeloma | June 2, 2023
At the ASCO meeting, researchers presented results of the trial with 22 months of follow-up.
Blood Cancers Today Staff WritersMyeloma | June 2, 2023
The ongoing, long-term CARTITUDE study will continue to follow these patients for safety and survival.
Leah SherwoodMyeloma | June 1, 2023
Sikander Ailawadhi, MD, speaks about the Mayo Clinic's efforts to address health care disparities.
Leah LawrenceMyeloma | May 31, 2023
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Cecilia BrownMyeloma | May 30, 2023
Bone marrow assessment of MRD is “prognostic for survival”, but bone marrow remains hypocellular at month one after ...
Cecilia BrownMyeloma | May 26, 2023
A recent study suggests the initial T-cell landscape could shape responses to bispecific T-cell engagers in MM.
Cecilia BrownMyeloma | May 25, 2023
The study included patients from the National Cancer Research Institute Myeloma XI trial.
Cecilia BrownMyeloma | May 23, 2023
The researchers assigned points to multiple factors to develop a risk score.
Cecilia BrownMyeloma | May 23, 2023
A new study suggests there is an “optimal” dose of carfilzomib for patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | May 23, 2023
The study was a retrospective pooled analysis of multicenter global clinical trials that submitted data to the US FDA.
Blood Cancer TalksBlood Cancer Talks | May 19, 2023
The episode was inspired by an article titled “The Underrepresented Majority" by Andrés Gómez-De León, MD.
Blood Cancer TalksBlood Cancer Talks | May 19, 2023
Dr. Gertz and the hosts provide an overview of risk-stratification approaches and clinical trials in smoldering MM.
Blood Cancer TalksBlood Cancer Talks | May 19, 2023
Dr. Costa discusses the multiple uses of MRD in MM.
Sagar Lonial, MD, FACPViewpoints | May 12, 2023
To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”
Leah SherwoodMyeloma | May 10, 2023
The FDA has set a target action date of December 16, 2023.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 4, 2023
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Larysa Sanchez, MDMyeloma | May 2, 2023
This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM. 
Thomas Martin, MDVideo Insights | May 1, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 1, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | April 27, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Thomas Martin, MDVideo Insights | April 27, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
Thomas Martin, MDVideo Insights | April 26, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
Thomas Martin, MDVideo Insights | April 26, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Thomas Martin, MDVideo Insights | April 25, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
Thomas Martin, MDVideo Insights | April 24, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
Leah SherwoodMeeting News | April 18, 2023
Dr. Tauro speaks about her presentation on novel strategies to overcome chemotherapy resistance in MM at AACR 2023.
Cecilia BrownMeeting News | April 17, 2023
The design of the bispecific antibody aims to overcome challenges with cytokine release syndrome.
Cecilia BrownMyeloma | April 14, 2023
The study used genomics to determine how often high-risk events "are missed at diagnosis and selected at relapse."
Cecilia BrownMyeloma | April 14, 2023
Novel agents did not significantly improve outcomes over conventional therapies in certain patients.
Leah LawrenceMyelodysplastic Syndromes | April 12, 2023
Novel targets are under investigation in several types of hematologic malignancies.
Sandy Wong, MDMyeloma | March 29, 2023
Dr. Wong hopes to see an expansion in the availability of new and novel treatments for myeloma.
Cecilia BrownMyeloma | March 28, 2023
The study included patients who had disease progression after participating in a bispecific antibody clinical trial.
Shambavi Richard, MDMyeloma | March 27, 2023
Dr. Richard hopes that one day she can confidently tell patients facing a multiple myeloma diagnosis that there is a cure. 
Sandy Wong, MDMyeloma | March 22, 2023
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Cecilia BrownMyeloma | March 22, 2023
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Sandy Wong, MDMyeloma | March 20, 2023
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Leah SherwoodMyeloma | March 17, 2023
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Cecilia BrownMyeloma | March 15, 2023
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Sandy Wong, MDMyeloma | March 14, 2023
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
Cecilia BrownMyeloma | March 14, 2023
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
Cecilia BrownMyeloma | March 10, 2023
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Sagar Lonial, MD, FACPMyeloma | March 6, 2023
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Cecilia BrownMyeloma | March 6, 2023
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
Cecilia BrownMyeloma | March 6, 2023
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.
Leah SherwoodMyeloma | February 27, 2023
The OPTIMUM/MUKnine clinical trial aimed to reduce the risk of relapse before and after AHSCT in ultrahigh-risk MM.
Leah SherwoodMyeloma | February 23, 2023
The new FDA decision follows its granting of Breakthrough Therapy Designation to elranatamab in November 2022.
Leah SherwoodPrint | February 20, 2023
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
Cecilia BrownMyeloma | February 16, 2023
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
Leah SherwoodMyeloma | February 15, 2023
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Cecilia BrownMyeloma | February 10, 2023
Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial.
Thomas Martin, MDMyeloma | February 7, 2023
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Leah SherwoodMyeloma | January 31, 2023
A triplet may improve PFS over lenalidomide alone in patients with multiple myeloma who underwent induction and AHSCT.
Cecilia BrownMyeloma | January 30, 2023
A new method to detect MRD in peripheral blood had an “unprecedented sensitivity” level in multiple myeloma.
Cecilia BrownMyeloma | January 27, 2023
Adding isatuximab to carfilzomib and dexamethasone improved PFS in multiple myeloma, regardless of relapse time.
Cecilia BrownMyeloma | January 25, 2023
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Cecilia BrownMyeloma | January 25, 2023
The FDA received a Biologics License Application for the use of talquetamab in patients with R/R multiple myeloma.
Leah SherwoodPrint | January 13, 2023
Elranatamab was granted Breakthrough Therapy Designation by the U.S. FDA for relapsed/refractory multiple myeloma.
Leah SherwoodPrint | January 13, 2023
The U.S. FDA has accepted for review and filed the New Drug Application for motixafortide.
Cecilia BrownMyeloma | January 9, 2023
Adding vorinostat to lenalidomide maintenance therapy did not improve survival over lenalidomide in multiple myeloma.
Shambavi Richard, MDVideo Insights | December 28, 2022
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
Ajai Chari, MDVideo Insights | December 27, 2022
Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.
Leah SherwoodMeeting News | December 27, 2022
Patients with multiple myeloma receiving BCMA-targeted therapies are at high risk of infectious complications.
Leah SherwoodMyeloma | December 26, 2022
Gary Schiller, MD, of the University of California, Los Angeles, discusses the STOMP study.
Amrita Krishnan, MD, FACPPrint | December 22, 2022
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 20, 2022
Robert Orlowski, MD, PhD, discusses bispecific antibodies and novel targets in myeloma with Chadi Nabhan, MD, MBA, FACP.
Chadi Nabhan, MD, MBA, FACPMyeloma | December 14, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more.
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 14, 2022
Thomas Martin, MD, discusses advances in frontline treatments for multiple myeloma, the need for novel agents, and more.
Cecilia BrownMyeloma | December 14, 2022
Patients with heavily pretreated multiple myeloma who received bispecific CAR T-cells had an OS rate of 83.9%.
Cecilia BrownVideo Insights | December 13, 2022
Sandy Wong, MD, discusses results from a phase I first-in-human study of alnuctamab in patients with relapsed/refractory MM.
Cecilia BrownMyeloma | December 12, 2022
The phase I UNIVERSAL trial showed allogeneic CAR-T therapy led to “significant and durable responses” in patients with ...
Leah LawrenceMyeloma | December 10, 2022
Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma.
Leah LawrenceMyeloma | December 10, 2022
Selinexor combinations had moderate efficacy in real-world patients with relapsed or refractory multiple myeloma.
Kerri FitzgeraldMyeloma | December 10, 2022
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
Cecilia BrownMyeloma | December 10, 2022
BCMA-directed CAR-T led to a CR in 75% in relapsed/refractory multiple myeloma who received allogeneic HSCT.
Cecilia BrownMyeloma | December 10, 2022
A new study suggests many interventional phase III clinical trials in myeloma didn't clearly define high-risk disease.
Leah LawrenceMeeting News | December 8, 2022
More genetic information is needed to investigate the link between racial ancestry and outcomes in multiple myeloma.
Leah LawrenceMeeting News | December 8, 2022
Selinexor plus rituximab, gemcitabine, cisplatin and dexamethasone had encouraging activity in patients with B-cell lymphoma.
Cecilia BrownLatest Issue | December 2, 2022
Iberdomide plus dexamethasone showed encouraging efficacy and safety in triple-class-exposed R/R myeloma anti-BCMA therapy.
Cecilia BrownMyeloma | December 2, 2022
A GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy had “promising” preliminary efficacy.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Cecilia BrownMyeloma | November 15, 2022
AgenT-797 is a scalable, off-the-shelf therapy that retains potent cytotoxicity after cryopreservation.
Cecilia BrownMyeloma | November 9, 2022
Findings support daratumumab plus lenalidomide and dexamethasone treatment for at least 18 months in MM...
Cecilia BrownMyeloma | November 9, 2022
Ciltacabtagene autoleucel led to responses in 61.5% of patients with multiple myeloma...
Leah SherwoodMyeloma | November 8, 2022
The phase III DREAMM-3 trial did not meet its primary endpoint...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Leah SherwoodMyeloma | October 25, 2022
The FDA has granted accelerated approval for the use of teclistamab in adults with relapsed or refractory multiple myeloma.
Leah SherwoodMyeloma | October 25, 2022
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Kerri FitzgeraldMyeloma | October 14, 2022
A single infusion of ciltacabtagene autoleucel led to impressive overall response rates...
Kerri FitzgeraldMyeloma | October 14, 2022
A new study suggests the current reference intervals for serum free light chain concentrations...
Kerri FitzgeraldMyeloma | October 14, 2022
Talquetamab demonstrated “highly promising efficacy” in heavily pretreated patients with...
Cecilia BrownMyeloma | October 13, 2022
The phase I/II MajesTEC-1 study demonstrated that teclistamab produced a high rate of deep...
Thomas Martin, MDMyeloma | October 13, 2022
We are entering the great era of immunotherapy in multiple myeloma.
Cecilia BrownMyeloma | October 13, 2022
The European Commission (EC) has granted marketing authorization for melphalan flufenamide...
Cecilia BrownMyeloma | October 13, 2022
The European Commission granted Conditional Marketing Authorization for teclistamab as a...
Leah SherwoodMyeloma | October 10, 2022
The committee overwhelmingly voted that melphalan flufenamide has not demonstrated benefit...
Leah SherwoodMyeloma | September 30, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Kerri FitzgeraldMyeloma | September 13, 2022
Antibiotic prophylaxis should be considered an option for patients with newly diagnosed multiple myeloma...
Kerri FitzgeraldMyeloma | September 13, 2022
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
Leah SherwoodMyeloma | September 12, 2022
CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma.
Leah SherwoodMeeting News | September 12, 2022
Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face...
Cecilia BrownMyeloma | September 2, 2022
Ciltacabtagene autoleucel led to an overall response rate of nearly 98% in heavily pretreated...
Cecilia BrownMyeloma | September 2, 2022
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Cecilia BrownMyeloma | September 2, 2022
Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable...
Cecilia BrownMyeloma | August 30, 2022
Doris Hansen, MD, of the Moffitt Cancer Center, spoke about the research during an oral abstract presentation at IMS.
Leah SherwoodMeeting News | August 30, 2022
Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease...
Leah SherwoodMyeloma | August 30, 2022
A single infusion of ciltacabtagene autoleucel “resulted in deep and durable responses" in CARTITUDE-2’s cohort A.
Leah SherwoodMyeloma | August 27, 2022
The data were from the phase III DETERMINATION trial...
Leah SherwoodMyeloma | August 26, 2022
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Cecilia BrownMeeting News | August 26, 2022
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
Leah SherwoodAcute Myeloid Leukemia | August 16, 2022
The report showed significant demographic and geographic imbalances in pivotal clinical trials leading to drug approval.
Leah SherwoodMyeloma | August 1, 2022
The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor...
Leah SherwoodMyeloma | July 29, 2022
The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label...
Cecilia BrownMyeloma | July 22, 2022
The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation...
Leah SherwoodMyeloma | July 18, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use issued...
Leah SherwoodMyeloma | July 7, 2022
The genetic signature consists of the genes WNT10A, DUSP1, and ETV7...
Leah SherwoodMyeloma | July 6, 2022
QXL138AM is a masked immunocytokine comprised of a CD138-targeted antibody fused with...
Leah LawrenceMyeloma | June 27, 2022
The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events...
Kerri FitzgeraldAcute Myeloid Leukemia | June 23, 2022
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
Leah LawrenceChronic Lymphocytic Leukemia | June 23, 2022
LAVA-051 consists of two single domain antibodies linked via a short five amino acid glycine-serine linker.
Leah SherwoodMyeloma | June 21, 2022
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Leah SherwoodMyeloma | June 21, 2022
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Leah LawrenceMyeloma | June 8, 2022
In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved...
Leah LawrenceMyeloma | June 8, 2022
IgD myeloma constitutes about 1% of myelomas and has worse prognosis than other subtypes...
Kerri FitzgeraldMyeloma | June 6, 2022
Belantamab mafodotin is a BCMA targeted antibody drug conjugate approved for adult patients...
Leah LawrenceMyeloma | May 31, 2022
The study explored adding daratumumab to RVd and VTd regimens for patients with multiple myeloma...
Leah LawrenceMyeloma | May 26, 2022
The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.
Kerri FitzgeraldMyeloma | May 24, 2022
Authors provide a case that demonstrates the real-world challenges of managing older, frail adults with newly diagnosed MM.
Kerri FitzgeraldMyeloma | May 24, 2022
Drs. Voorhees and Martin debate frontline treatment for fit patients with multiple myeloma.
Leah LawrenceMyeloma | May 19, 2022
A small study observed a link between BMI and progression of monoclonal gammopathy of undetermined significance.
Leah LawrenceMyeloma | May 19, 2022
However, the three-drug combination improved survival in the relapsed/refractory setting.
Leah LawrenceMyeloma | May 12, 2022
Adding ixazomib to this treatment regimen did not improve survival outcomes, according to results of the MUKeight trial
Leah LawrenceMyeloma | May 12, 2022
A study has identified a very high prevalence of all monoclonal gammopathies in high-risk individuals aged 50 years or older.
Leah LawrenceMyeloma | May 10, 2022
A study identified differences in molecular features that may drive clinical disparities seen in patients with myeloma.
Leah LawrenceMyeloma | May 5, 2022
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Ariel DeMaioMyeloma | May 3, 2022
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Leah LawrenceMyeloma | May 2, 2022
A phase I study is underway to assess ALLO-605.
Leah LawrenceMyeloma | April 25, 2022
Minimal residual disease (MRD) negativity after autologous hematopoietic cell transplantation (AHCT) was associated with ...
Leah LawrenceMyeloma | April 22, 2022
Study finds that a third dose of the COVID-19 vaccine increased antibodies in multiple myeloma patients, regardless of prior ...
Leah LawrenceMyeloma | April 21, 2022
Immune checkpoint inhibitors can lower the risk of developing neurologic adverse events (NAEs) more than other cancer ...
Sabrina AhleMyeloma | March 22, 2022
New legislation would set time limits around FDA accelerated approvals.
Sabrina AhleMyeloma | March 12, 2022
According to a recent HHS report, the percentage of uninsured Black Americans has decreased since the ACA became law in 2010.
Sabrina AhleMyeloma | March 12, 2022
Cilta-cel has been approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who have ...
Leah LawrenceTransplantation & Cellular Therapy | March 2, 2022
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Patrick DalyMyeloma | March 2, 2022
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
Ariel DeMaioAggressive B-Cell Lymphoma | March 2, 2022
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Brandon MayMyeloma | March 2, 2022
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Sabrina AhleMyeloma | March 2, 2022
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Sagar Lonial, MD, FACPMyeloma | March 2, 2022
Welcome to the second issue of Blood Cancers Today, where we’re continuing to share stories and updates on data that ...
Jacob Laubach, MD, MPPMyeloma | February 24, 2022
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Jacob Laubach, MD, MPPMyeloma | February 24, 2022
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Sabrina AhleMyeloma | February 22, 2022
Patients with hematologic malignancies have a significantly higher rate of composite thrombotic outcomes.
Sabrina AhleMantle Cell Lymphoma | February 8, 2022
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Sabrina AhleMyeloma | January 21, 2022
Daratumumab and hyaluronidase-fihj, in combination with carfilzomib and dexamethasone (Kd), has received U.S. Food and Drug ...
Sagar Lonial, MD, FACPMyeloma | January 21, 2022
The pace of change in blood cancers is quite dramatic, and new paradigms of treatment, assessment, and pathogenesis occur ...
Noopur Raje, MDMyeloma | January 15, 2022
Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217.
Noopur Raje, MDMyeloma | January 15, 2022
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
Rebecca AraujoMyeloma | November 19, 2021
In a study, researchers sought to calculate healthcare costs associated with triple class exposure (TCE) to multiple myeloma ...
Rebecca AraujoMantle Cell Lymphoma | November 15, 2021
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Rebecca AraujoHodgkin Lymphoma | November 12, 2021
Older patients are at a significantly increased risk of immune-related AEs.
Rebecca AraujoMyeloma | October 26, 2021
A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with ...
Rob DillardMyeloma | October 21, 2021
Researchers sought to discern the effect of COVID-19 countermeasures on treatment outcomes in a patient population receiving ...
Myeloma | October 21, 2021
Several factors are correlated with palliative care use among patients with various cancers, but literature is lacking on ...
Sabrina AhleMyeloma | October 21, 2021
The LocoMMotion study provides real-world data on outcomes in triple-class exposed MM patients receiving standard of care.
Vikas A. Gupta, MD, PhDMyeloma | October 21, 2021
Vikas A. Gupta, MD, PhD and Lawrence H. Boise, PhD ...
Faith Davies, MBBCh, MD MRCP, MRCPathMyeloma | October 21, 2021
Faith Davies, MBBCh, MD MRCP, MRCPath ...
Rebecca AraujoMyeloma | October 18, 2021
A study published in Environment International reported an elevated risk of multiple myeloma (MM) among female agricultural ...
Rebecca AraujoMyeloma | October 18, 2021
In a phase II prospective clinical trial, researchers evaluated the effectiveness of a personalized sequential therapy for ...
Rebecca AraujoAcute Lymphoblastic Leukemia | October 11, 2021
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Rob DillardMyeloma | October 5, 2021
Researchers of a study investigated the relationship between chronic kidney disease and multiple myeloma (MM) in a South ...
Rebecca AraujoTransplantation & Cellular Therapy | September 28, 2021
Black patients with multiple myeloma (MM) who receive upfront hematopoietic autologous cell transplantation (ASCT) have ...
Rebecca AraujoChronic Lymphocytic Leukemia | September 24, 2021
Racial and ethnic minorities experience well-documented disparities across the cancer trajectory.
Rebecca AraujoAcute Lymphoblastic Leukemia | September 23, 2021
The research team intends to evaluate the biological mechanisms behind blood clotting in patients with cancer.
Rob DillardMyeloma | September 7, 2021
Socioeconomic status (SES) and race/ethnicity should be considered when planning multiple myeloma (MM) interventions, ...
Rob DillardMyeloma | September 7, 2021
Socioeconomic factors play a big role in multiple myeloma (MM) disparities, according to a study published in ...
Rebecca AraujoMyeloma | August 31, 2021
A study published in Blood Advances found that a gene linked to multiple myeloma (MM) prognosis is expressed less frequently ...
Rebecca AraujoMyeloma | August 31, 2021
A study published in JCO Global Oncology evaluated mid-to long-term outcomes of multiple myeloma (MM) treatment in Peru. ...
Rebecca AraujoMyeloma | August 23, 2021
A study of patients with multiple myeloma (MM) in Latin America found that major bone complications are linked to increased ...
Rebecca AraujoTransplantation & Cellular Therapy | August 23, 2021
A study published in Bone Marrow Transplantation evaluated whether patient characteristics impacted the timeline to return to ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | August 18, 2021
Experts focus on the latest news and clinical development and impact for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | August 18, 2021
Experts discuss treatment options related to anti-CD38 based combination triplets.
Myeloma | August 18, 2021
Ola Landgren, MD, PhD, Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami ...
Elisa S. Weiss, PhDMyeloma | August 18, 2021
Elisa S. Weiss, PhD, Senior Vice President, Education, Services & Health Research, LLS, New York ...
Manisha Bhutani, MDMyeloma | August 18, 2021
Redefining Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma ...
Myeloma | August 18, 2021
Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD ...
Urvi A. Shah, MDMyeloma | August 18, 2021
Urvi A. Shah, MD, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York ...
María-Victoria Mateos, MD, PhDMyeloma | August 17, 2021
María-Victoria Mateos, MD, PhD, Borja Puertas MD, and Veronica González-Calle MD, PhD ...
Rob DillardTransplantation & Cellular Therapy | August 12, 2021
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
Rob DillardAggressive B-Cell Lymphoma | August 10, 2021
A cross-sectional survey study involved patients treated in Mexico City for lymphoma, leukemia, or multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | August 6, 2021
Drs. Saad Usumani and Sydney Lu discuss adjusting multiple myeloma treatments to the realities of the COVID-19 pandemic.
Rob DillardMyeloma | August 6, 2021
A study found no discernible difference in the usage rate of hematopoietic cell transplantation (HCT) between Black and White ...
Rob DillardMyeloma | July 29, 2021
A recent study shows that multiple sites of extramedullary-bone related (EMB) lesions are poor prognostic factors for newly ...
Rob DillardMyeloma | July 27, 2021
A study found sex differences in high-risk cytogenetics among patients with multiple myeloma (MM), though these differences ...
Rob DillardMyeloma | July 27, 2021
Clarithromycin plus lenalidomide and dexamethasone for the treatment of multiple myeloma (MM) did not offer a survival ...
Rob DillardMyeloma | July 26, 2021
Patient race and ethnicity were bound to be associated with hematopoietic stem/progenitor cells (HSPC) mobilization, ...
Rob DillardMyeloma | July 26, 2021
An analysis of Asian patients with multiple myeloma found that treatment with subcutaneous daratumumab (DARA SC) was ...
Rob DillardMyeloma | July 22, 2021
A study indicates that BCL2 dependence, as well as CD38 expression, are significantly linked with the differentiation ...
Rob DillardMyeloma | July 15, 2021
Elevated membrane expression of junctional adhesion molecule A (JAM-A) on multiple myeloma endothelial cells (MMECs) ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 13, 2021
Communication between the clinician and patient, as a two-way conversation, clarity on goals for treatment and treatment ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 7, 2021
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
Rob DillardMyeloma | June 30, 2021
Insurance status was associated with survival among patients with multiple myeloma (MM), according to new study results ...
Rob DillardMyeloma | June 30, 2021
A new study reports on county-level socioeconomic disparities in the distribution of multiple myeloma (MM) clinical trial ...
Rob DillardMyeloma | June 30, 2021
A study found that a high expression of the coding gene human leukocyte antigen-E (HLA-E) is associated with advanced disease ...
Rob DillardMyeloma | June 30, 2021
Researchers for a recent study evaluated the prevalence and characteristics of second primary malignancies (SPMs) in Black ...
Rob DillardTransplantation & Cellular Therapy | June 30, 2021
A study did not observe racial disparities in the use of autologous hematopoietic cell transplantation (HCT) consolidative ...
Rebecca AraujoMyeloma | June 14, 2021
Although physical activity and exercise programs have shown benefit for patients with multiple myeloma (MM), clinical ...
Rebecca AraujoMyeloma | June 11, 2021
In patients with multiple myeloma (MM), higher patient-rated pain severity was found to be significantly associated with ...
Rebecca AraujoMyeloma | June 7, 2021
Treatment with a regimen of bortezomib, melphalan, and prednisone (VMP) with or without daratumumab (D-VMP) led to similar ...
Rebecca AraujoMyeloma | June 7, 2021
Incidence of multiple myeloma (MM) has more than doubled globally since 1990, according to an analysis published in BMC ...
Rebecca AraujoMyeloma | May 24, 2021
Real-world data showed that upfront autologous hematopoietic stem cell transplantation (AHCT) for treatment of multiple ...
Rebecca AraujoMyeloma | May 17, 2021
A predictive tool may help primary care physicians identify patients at high-risk of multiple myeloma (MM), according to a ...
Rebecca AraujoMyeloma | May 17, 2021
Researchers from The Mount Sinai Health System in New York City evaluated racial disparities in time to autologous ...
Rebecca AraujoMyeloma | May 17, 2021
A study published in the Annals of Hematology used real-world evidence to conduct head-to-head comparisons of triplet ...
Rebecca AraujoMyeloma | May 10, 2021
A study published in Clinical Lymphoma, Myeloma, & Leukemia evaluated the efficacy of intravenous immunoglobin (IVIG) to ...
Nikhil Munshi, MDTransplantation & Cellular Therapy | April 27, 2021
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
Peter Voorhees, PhDMyeloma | April 27, 2021
Peter Voorhees, PhD ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | April 27, 2021
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...
Rebecca AraujoMyeloma | April 26, 2021
A study from researchers at Sungkyunkwan University in Seoul, South Korea assessed how depression impacts ...
Rebecca AraujoMyeloma | April 21, 2021
A study published in The Lancet Haematology reviewed responses to the first dose of the SARS-CoV-2 vaccine in patients with ...
Douglas Sborov, MD, MSMyeloma | April 9, 2021
Douglas Sborov, MD, MS, discusses the impact of the COVID-19 pandemic on treatment and care for patients with MM.
Douglas Sborov, MD, MSMyeloma | April 9, 2021
Douglas Sborov, MD, speaks about recent initiatives to expand eligibility to multiple myeloma clinical trials.
Rebecca AraujoMyeloma | April 9, 2021
On March 10, 2021, the National Comprehensive Cancer Network Vaccination Advisory Committee released their recommendations ...
Rebecca AraujoMyeloma | April 2, 2021
On March 31, 2021, the FDA extended the indication of isatuximab for use in combination with carfilzomib and dexamethasone ...
Rebecca AraujoTransplantation & Cellular Therapy | March 30, 2021
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with ...
Rebecca AraujoMyeloma | March 11, 2021
A study published in the European Journal of Haematology calculated costs and survival outcomes associated with ...
Rebecca AraujoMyeloma | March 11, 2021
Two studies that assessed multiple myeloma care in Latin America found significant differences in access and outcomes ...
Rebecca AraujoTransplantation & Cellular Therapy | March 9, 2021
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the burden of outpatient autologous hematopoietic ...
Rebecca AraujoMyeloma | March 9, 2021
A study published in BMC Medicine evaluated physical and mental health-related outcomes in patients with multiple myeloma ...
Parameswaran Hari, MDMyeloma | March 5, 2021
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
Rebecca AraujoMyeloma | March 4, 2021
A study published in the Journal of Medical Economics calculated costs associated with the use of different proteasome ...
Parameswaran Hari, MDMyeloma | March 4, 2021
Parameswaran Hari, MD, speaks about myeloma research presented at the virtual 2020 ASH Annual Meeting.
Rebecca AraujoMyeloma | March 3, 2021
On March 1, 2021, the U.S. Food and Drug Administration granted accelerated approval to melphalan flufenamide (melflufen) in ...
Myeloma | March 2, 2021
A study published online in the Journal of Oncology Pharmacy Practice calculated economic outcomes of patients with ...
Myeloma | March 2, 2021
An early access treatment protocol (EAP) found that daratumumab monotherapy was safe in a population of patients with heavily ...
Rebecca AraujoTransplantation & Cellular Therapy | March 2, 2021
The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with ...
Rebecca AraujoMyeloma | March 2, 2021
Findings presented at the ASH 2020 Annual Meeting & Exposition found that almost half of patients with multiple myeloma (MM) ...
Rebecca AraujoMyeloma | February 22, 2021
In a collaborative effort, researchers from the Dana-Farber Cancer Institute, the U.S. Food and Drug Administration, and the ...
Rebecca AraujoMyeloma | February 17, 2021
A study published in the British Journal of Cancer assessed whether esterase gene expression is of clinical significance in ...
Rebecca AraujoTransplantation & Cellular Therapy | February 17, 2021
Patients with multiple myeloma who underwent double autologous hematopoietic cell transplantation did not have better overall ...
Advertisement
Advertisement
Advertisement
Advertisement
Latest News

September 22, 2023